Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologi - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologi - zdravilo lucentis je navedeno v odraslih za:zdravljenje neovascular (mokro) starostna degeneracija rumene pege (amd)zdravljenje vida zaradi choroidal neovascularisation (cnv)zdravljenje vida zaradi diabetično degeneracija edem (dme)zdravljenje vida zaradi degeneracija edem sekundarnega do mrežnice vene (veja rvo ali centralne rvo).

Evropska unija - slovenščina - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologi - eylea je primerna za odrasle, za zdravljenje:neovascular (mokro) starostna degeneracija rumene pege (amd);vida zaradi degeneracija edem sekundarnega do mrežnice vene (veja rvo ali centralne rvo);vida zaradi diabetično degeneracija edem (dme);vida zaradi kratkovidna choroidal neovascularisation (kratkovidna cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumab - mokra makularna degeneracija - oftalmologi - treatment of neovascular (wet) age-related macular degeneration (amd).